Although the detection of VPS13A gene mutations and the identification of chorein protein deficiency by Western blot remain the gold standard for diagnosis, the proposed multi-dimensional framework—integrating progressive motor disorders, neuropsychiatric manifestations, and hematological features—has significantly improved clinicians' ability to identify ChAc in overlapping phenotypes. The gene discussed is VPS13A; the disease is chorea-acanthocytosis.